Skip to main content
SpringerLink
Log in

Drug Interactions with Irbesartan

  • Review Articles
  • Drug Interactions
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Irbesartan is an angiotensin II receptor antagonist indicated for the treatment of patients with hypertension. Although irbesartan does not require biotransformation for its pharmacological activity, it does undergo metabolism via the cytochrome P450 (CYP) 2C9 isoenzyme and negligible metabolism by the CYP3A4 isoenzyme. The long term treatment of patients with hypertension is generally required for effective management of the disease, and the use of concurrent medications is usually inevitable. This paper reviews the drug and food interaction trials involving irbesartan that have been conducted to date.

Based on the available literature, no significant interactions have been identified between irbesartan and hydrochlorothiazide, nifedipine, simvastatin, tolbutamide, warfarin, magnesium and aluminum hydroxides, digoxin or food. Fluconazole did increase the steady-state peak plasma concentration (by 19%) and area under the concentration-time curve (by 63%) of irbesartan, but these increases are not likely to be clinically significant.

In summary, irbesartan has demonstrated minimal potential for drug or food interactions in trials conducted to date.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cazaubon C, Gougat J, Bousquet F, et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265: 826–34

    PubMed  CAS  Google Scholar 

  2. AVAPRO® (irbesartan). Product Information. In: Physician’s Desk Reference. Montvale (NJ): Medical Economics Data Production Company, 2000: 818–20

    Google Scholar 

  3. Reeves RA, Lin C-S, Kassler-Taub K, et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998; 31: 1311–6

    Article  PubMed  CAS  Google Scholar 

  4. Pool JL, Guthrie RM, Littlejohn III TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild- to-moderate hypertension. Am J Hypertens 1998; 11: 462–70

    Article  PubMed  CAS  Google Scholar 

  5. Simon TA, Gelarden T, Freitag SA, et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1998; 82: 179–82

    Article  PubMed  CAS  Google Scholar 

  6. Kaplan NM. Implications for cost-effectiveness. Combination therapy for systemic hypertension. Am J Cardiol 1995; 76: 595–7

    Article  PubMed  CAS  Google Scholar 

  7. Waeber B, Brunner HR. Main objectives and new aspects of combination treatment ofhypertension. J Hypertens 1995; 13 Suppl. 2: S15–9

    Article  CAS  Google Scholar 

  8. Littlejohn T, Saini R, Kassler-Taub K, et al. Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies. Clin Exp Hypertens 1999; 22: 1273–95

    Article  Google Scholar 

  9. Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angioten- sin-II receptor antagonists. Eur J Clin Pharmacol 2000; 56: 135–40

    Article  PubMed  CAS  Google Scholar 

  10. Bourrie M, Meunier V, Berger Y, et al. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver micro- somes. Drug Metab Dispos 1999 Feb; 27: 288–96

    PubMed  CAS  Google Scholar 

  11. Welling PG. Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm 1977; 5: 291–334

    PubMed  CAS  Google Scholar 

  12. Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet 1978; 3: 337–51

    Article  PubMed  CAS  Google Scholar 

  13. Diovan® (valsartan). Product information. In: Physicians’ desk reference. Montvale (NJ): Medical Economics Data Production Company, 2001: 2166

    Google Scholar 

  14. Cozaar® (losartan). Product information. In: Physicians’ desk reference. Montvale (NJ): Medical Economics Company, 2001: 1902

    Google Scholar 

  15. Marino MR, Vachharajani NN, Hadjilambris OW, et al. Lack of effect of irbesartan on the pharmacokinetics of hydrochlorothiazide in healthy subjects [abstract]. J Clin Pharmacol 1999; 39: 977

    Google Scholar 

  16. Marino MR, Langenbacher KM, Ford NF, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartan. Clin Drug Invest 1997; 14: 383–91

    Article  CAS  Google Scholar 

  17. Marino MR, Hammett JL, Ferreira I, et al. Effect of nifedipine on the steady-state pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Cardiovasc Pharmacol Ther 1998; 3: 111–8

    Article  PubMed  CAS  Google Scholar 

  18. Marino MR, Vachharajani NN, Hadjilambris OW. Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. J Clin Pharmacol 2000; 40(8): 875–9

    Article  PubMed  CAS  Google Scholar 

  19. Marino MR, Langenbacher KM, Mangold B, et al. Lack of drug interactions with irbesartan: a summary of five pharmacokinetic studies [abstract]. J Hypertens 1998; 16 Suppl. 2: S248

    Google Scholar 

  20. Mangold B, Gielsdorf W, Marino MR. Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin. Eur J Clin Pharmacol 1999; 55: 593–8

    Article  PubMed  CAS  Google Scholar 

  21. Kovacs SJ, Wilton JH, Blum RA. Steady state (SS) pharmacokinetics (PK) of irbesartan alone and in combination with fluconazole (F) [abstract]. Clin Pharmacol Ther 1999; 65:132

    Google Scholar 

  22. Escolar M, Lopez de Ocariz A, Simon M, et al. Effects of antacids on irbesaran pharmacokinetics [abstract]. Meth Find Exp Clin Pharmacol 1998; 20 Suppl. A: 53

    Google Scholar 

  23. Marino MR. Effect of irbesartan on the steady-state pharmacokinetics of digoxin in healthy male subjects [abstract]. ASHP Midyear Clinical Meeting; 1998 Dec; 33: P–278E

    Google Scholar 

  24. Vachharajani NN, Shyu WC, Mantha S, et al. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J Clin Pharmacol 1998; 38: 433–6

    PubMed  CAS  Google Scholar 

  25. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12 797–805

    Article  PubMed  CAS  Google Scholar 

  26. Brouwer RML, Bolli P, Erné P, et al. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: S88–S91

    Article  PubMed  Google Scholar 

  27. Donnelly R, Elliot HL, Meredith PA, et al. An evaluation of the pharmacodynamics and pharmacokinetics of nicardipine combined with enalapril in essential hypertension. J Car- diovasc Pharmacol 1987; 10: 723–7

    Article  CAS  Google Scholar 

  28. Singer DRJ, Markandu ND, Shore AC, et al. Captopril and nifedipine in combination for moderate to severe essential hypertension. Hypertension 1987; 9: 629–33

    Article  PubMed  CAS  Google Scholar 

  29. Guengerich FP, Martin MV, Beaune PH, et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261: 5051–60

    PubMed  CAS  Google Scholar 

  30. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997 Oct; 25: 1191–9

    PubMed  CAS  Google Scholar 

  31. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209–15

    Article  PubMed  CAS  Google Scholar 

  32. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525–38

    Article  PubMed  CAS  Google Scholar 

  33. Back DJ, Sutcliffe F, Tjia JF. Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat. Br J Pharmacol 1984; 81: 557–62

    Article  PubMed  CAS  Google Scholar 

  34. The effect of concomitant administration of irbesartan on the steady-state pharmacokinetics of tolbutamide in healthy subjects. Princeton (NJ): Bristol Meyer Squibb, 1997 (Data on file)

  35. Diflucan® (fluconazole). Product information. In: Physicians’ desk reference. Montvale (NJ): Medical Economics Data Production Company, 2001: 2487

    Google Scholar 

  36. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111–80

    Article  PubMed  CAS  Google Scholar 

  37. D’Arcy PF, McElnay JC. Drug-antacid interactions: assessment of clinical importance. Drug Intell Clin Pharm 1987; 21: 607–17

    PubMed  Google Scholar 

  38. Shionoiri H. Pharmacokinetic drug interactions with ACE in hibitors. Clin Pharmacokinet 1993; 25: 20–58

    Article  PubMed  CAS  Google Scholar 

  39. Brunton LL. Agents for control of gastric acidity and treatment of peptic ulcers. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 901–15

    Google Scholar 

  40. Sadowski DC. Drug interactions with antacids: mechanisms and clinical significance. Drug Saf 1994; 11: 395–407

    Article  PubMed  CAS  Google Scholar 

  41. Lanoxin® (digoxin). Product information. In: Physicians’ desk reference. Montvale (NJ): Medical Economics Data Production Company, 2001: 1432

    Google Scholar 

  42. Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–46

    Article  Google Scholar 

  43. World Health Organization-International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999 Feb; 17: 151–83

    Google Scholar 

  44. Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998 May; 26 (5): 408–17

    PubMed  CAS  Google Scholar 

  45. Kaukonen K-M, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998 Feb; 53: 445–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

the Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, New Jersey, USA financially supported this work.

Author information

Authors and Affiliations

  1. Bristol- Myers Squibb Pharmaceutical Research Institute, P. O. Box 4000, Princeton, New Jersey, NJ 18543, USA

    Maria R. Marino & Nimish N. Vachharajani

Authors
  1. Maria R. Marino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nimish N. Vachharajani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marino, M.R., Vachharajani, N.N. Drug Interactions with Irbesartan. Clin Pharmacokinet 40, 605–614 (2001). https://doi.org/10.2165/00003088-200140080-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200140080-00004

Keywords

Search

Navigation